Stay informed, stay ahead.
AstraZeneca and Daiichi Sankyo have announced that their new drug Datroway significantly improved survival in patients with aggressive triple-negative breast cancer (TNBC). The results were revealed at the European Society for Medical Oncology (ESMO) Congress in Berlin. In the trial, patients receiving Datroway achieved a median overall survival of 23.7 months versus 18.7 months for those treated with standard chemotherapy….
The U.S. Food and Drug Administration (FDA) has expanded approval for Tezspire (tezepelumab-ekko), a drug co-developed by Amgen and AstraZeneca. Starting now, it can be used as a maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in people aged 12 and older. CRSwNP is a long-term sinus condition featuring inflammation and non-cancerous growths called…
Washington — The Trump administration announced Friday that it has reached a landmark agreement with AstraZeneca to lower the cost of prescription drugs in the United States, expanding the administration’s push to pressure pharmaceutical companies into offering “most-favored nation” pricing. The deal mirrors a similar pact reached with Pfizer last month and marks another major…
